Purdue Pharma to Settle Oklahoma Opioid Lawsuit for $270 Million
Purdue Pharma LP and the Sackler family will pay $270 million to settle the state of Oklahoma’s claims that illegal marketing of the Oxycontin painkiller devastated local communities, the first accord in a wave of lawsuits faced by the drugmaker.
The settlement comes two months before the scheduled start of a trial against Purdue Pharma, Johnson & Johnson and Teva Pharmaceutical Industries Ltd. in Norman, Oklahoma. Details of the agreement are scheduled to be announced by the state later Tuesday.
Oklahoma claims the three opioid makers understated the risks of prescription painkillers and overstated their benefits, fueling an epidemic that’s costing its communities tens of millions of dollars for treatment and policing. The companies and others are also battling claims by three dozen states and 1,600 U.S. cities and counties, but those suits are pending in another court and the first trial isn’t until the fall.
Still, Purdue’s settlement could help set the terms for other jurisdictions and companies looking to resolve the opioid litigation.
In its suit, Oklahoma sought $25 billion in damages and penalties over Purdue’s push to lure doctors into prescribing Oxycontin for unauthorized uses to generate billions in profits for the company. While doctors have wide discretion to prescribe medicines beyond what they’ve been approved to treat, drugmakers are limited to marketing their products for just ailments approved by regulators.
The Sackler family, which owns the drugmaker, is accused of making billions over the abuse of Oxycontin that the company’s marketing allegedly fueled. The family made more than $4 billion between 2008 and 2016, according to a recently unsealed opioid suit filed by the Massachusetts Attorney General.
The settlement will allow Stamford, Connecticut-based Purdue to avoid filing for bankruptcy at least for now, according to people familiar with the matter, who declined to speak publicly about the deal because they weren’t authorized to do so. Craig Landau, Purdue’s chief executive officer, confirmed in a March 8 interview with the Washington Post that “bankruptcy is an option” to deal with the wave of opioid suits that threaten the pharmaceutical company’s financial strength.
A Chapter 11 filing would shield Purdue from litigation by imposing a stay on all U.S. suits and allow the privately held drugmaker to consolidate its legal costs and expenses. Experts say taking the cases out of the regular court system and putting them before a single bankruptcy judge likely will allow Purdue to pay less in settlements.
The agreement in Oklahoma is the first in a group of opioid lawsuits against Purdue. More than a decade ago, West Virginia settled a case against Purdue over its marketing of Oxycontin, which came on the U.S. market in 1996.
Lawyers for Oklahoma and Purdue have been in talks for months, according to the people. The settlement negotiations were overseen by a court-appointed mediator. Judge Thad Balkman refused requests by Purdue, J&J and Teva to delay the May 28 trial. On Monday, the state’s Supreme Court upheld Balkman’s decision to push ahead with the trial, making Oklahoma the first state in the nation to try claims against opioid makers.
In 2016, there were 444 opioid-related overdose deaths in Oklahoma, which left it ranked 28th in the U.S. for such deaths, according to data analyzed by the Centers for Disease Control and Prevention. The year before, the number of opioid prescriptions Oklahoma doctors wrote exceeded the state’s population of four million, according to government statistics.
The state’s suit sought millions in damages for the current costs of dealing with the opioid epidemic and billions in future costs tied to counseling, health-care and social services for children orphaned by overdoses, according to court filings in Oklahoma’s case.
The case is State of Oklahoma v Purdue Pharma LP, No. ZCJ-2017-816, Oklahoma District Court for Cleveland County (Norman).